Infliximab for Injection
Efficacy and safety are equivalent to the original drug (Johnson & Johnson/Merck & Co.
The first infliximab biosimilar marketed in China
Infliximab for Injection (Reminton), a recombinant anti-TNF-alpha chimeric monoclonal antibody, was approved for marketing by the National Medical Products Administration (NMPA) on July 14, 2021. It is the first infliximab biosimilar marketed in China. Taking advantage of CHO cell expression system, Remin_x005f ton has been proved with good efficacy, better safety, and lower immunogenicity in clinical studies.
Indications:
Crohn's disease in adults and children over 6 years of age, stulizing Crohn's disease,
ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, and psoriasis.
Recommended reading
Related products
-
Recombinant Collagen Repair Mask
Contact UsCOLLAGEN SUPPLEMENTATION – A SCIENTIFIC SOLUTION TO AGING SKIN
-
Prune/Plum Powder Extract
Contact UsPlums are delicious and nutritious fruits that offer a variety of health benefits. They are rich in vitamins, minerals, antioxidants, and dietary fiber. Here are some of the key health benefits associ
-
Metal casings
Contact UsYancheng Zhongming New Materials Co., Ltd. is located in Yancheng City, Jiangsu Province.
-
Durable moving bed carpet
Contact UsThe vacuum cleaner mobile test bench, model ZYXCQ-8A, is an intelligent aging test bench designed and implemented based on the complete machine testing requirements of the IEC-60312 standard.
Reviews
There are no reviews yet.